Management of Localized Non-Small Cell Lung Cancer with EGFR Tumor Mutations with Dr Roy Herbst - a podcast by Research To Practice

Dr Roy Herbst from the Yale Cancer Center discusses the clinical data on and optimal use of adjuvant osimertinib for patients with resected non-small cell lung cancer and an EGFR mutation.
CME information and select publications here (http://www.researchtopractice.com/OncologyTodayEGFRNSCLC21).

Further episodes of Oncology Today with Dr Neil Love

Further podcasts by Research To Practice

Website of Research To Practice